EDITAS MEDICINE, INC. Restructuring and Related Cost, Number of Positions Eliminated, Period Percent
EDITAS MEDICINE, INC. (EDIT) reported Restructuring and Related Cost, Number of Positions Eliminated, Period Percent of 65.00% for the 19-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent · last filed 2026-08-05
- 2026-06-30: .
- 2026-03-31: Restructuring and Related Cost, Number of Positions Eliminated, Period Percent 16 month 65.00%.
- 2025-12-31: Restructuring and Related Cost, Number of Positions Eliminated, Period Percent 13 month 65.00%.
- 2025-09-30: Restructuring and Related Cost, Number of Positions Eliminated, Period Percent 10 month 65.00%.
| Period end | Restructuring and Related Cost, Number of Positions Eliminated, Period Percent 7 month | Restructuring and Related Cost, Number of Positions Eliminated, Period Percent 10 month | Restructuring and Related Cost, Number of Positions Eliminated, Period Percent 13 month | Restructuring and Related Cost, Number of Positions Eliminated, Period Percent 16 month | Restructuring and Related Cost, Number of Positions Eliminated, Period Percent 19 month |
|---|---|---|---|---|---|
| 2026-06-30 | 65.00% 10-Q · filed 2026-08-05 | ||||
| 2026-03-31 | 65.00% 10-Q · filed 2026-05-05 | ||||
| 2025-12-31 | 65.00% 10-K · filed 2026-03-09 | ||||
| 2025-09-30 | 65.00% 10-Q · filed 2025-11-10 | ||||
| 2025-06-30 | 65.00% 10-Q · filed 2025-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |